Endometrial serous adenocarcinoma

Summary

Endometrial serous adenocarcinoma (MONDO:0006196) is a disease with 3 cohort genes and 50 clinical trials. Molecularly, ERBB2 Amplification confers sensitivity to Trastuzumab + Carboplatin/Paclitaxel Regimen in Endometrial Serous Adenocarcinoma (CIViC Level B); 3 further subtype–drug associations are mapped below. Top therapeutic interventions include cisplatin, cabozantinib, and metformin.

At a glance

• Cohort genes: 3
• ClinVar variants: 1
• Clinical trials: 50
• Precision-medicine evidence (CIViC): 4 subtype–drug associations

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endometrial serous adenocarcinoma
Mondo ID	MONDO:0006196
EFO	EFO:1000238
DOID	DOID:5750
ICD-11	225222541
NCIT	C27838
UMLS	C0854924
MedGen	1659908
Is cancer (heuristic)	no

Also known as: body of uterus serous adenocarcinoma · endometrial serous adenocarcinoma · serous endometrial adenocarcinoma · uterine corpus serous adenocarcinoma · uterine papillary serous carcinoma · uterine serous adenocarcinoma · uterine serous carcinoma · uterine serous carcinoma/uterine papillary serous carcinoma · uterine serous papillary adenocarcinoma

Data availability: 1 ClinVar variant · 31 cell lines.

Disease family

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › endometrial serous adenocarcinoma

Related subtypes (8): endometrial carcinoma, uterus carcinoma in situ, cervical carcinoma, squamous cell carcinoma of the corpus uteri, undifferentiated carcinoma of the corpus uteri, papillary carcinoma of the corpus uteri, adenoid cystic carcinoma of the corpus uteri, transitional cell carcinoma of the corpus uteri

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

1 retrieved; paginated sample, class counts are floors:

1 pathogenic

ClinVar	Variant (HGVS)	Gene	Classification	Review
1174013	Single allele	ATM	Pathogenic	no assertion criteria provided

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 12 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
ERBB2	Orphanet:213726	Serous carcinoma of the corpus uteri
ERBB2	Orphanet:2800	Extramammary Paget disease
ERBB2	Orphanet:388	Hirschsprung disease
ERBB2	Orphanet:99976	Adenocarcinoma of the oesophagus and oesophagogastric junction
ATM	Orphanet:100	Ataxia-telangiectasia
ATM	Orphanet:1331	Familial prostate cancer
ATM	Orphanet:145	Hereditary breast and/or ovarian cancer syndrome
ATM	Orphanet:227535	Hereditary breast cancer
ATM	Orphanet:370109	Ataxia-telangiectasia variant
ATM	Orphanet:440437	Familial colorectal cancer Type X
ATM	Orphanet:52416	Mantle cell lymphoma
ATM	Orphanet:67038	B-cell chronic lymphocytic leukemia

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
civic_only	2
multi_evidence	1

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
CCNE1	HGNC:1589	ENSG00000105173	P24864	G1/S-specific cyclin-E1	civic_evidence
ERBB2	HGNC:3430	ENSG00000141736	P04626	Receptor tyrosine-protein kinase erbB-2	civic_evidence
ATM	HGNC:795	ENSG00000149311	Q13315	Serine-protein kinase ATM	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
CCNE1	G1/S-specific cyclin-E1	Essential for the control of the cell cycle at the G1/S (start) transition.
ERBB2	Receptor tyrosine-protein kinase erbB-2	Protein tyrosine kinase that is part of several cell surface receptor complexes, but that apparently needs a coreceptor for ligand binding.
ATM	Serine-protein kinase ATM	Serine/threonine protein kinase which activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor.

Protein-family classification

Druggable: 2 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.67

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Kinase	2	18.5×	0.008
Other/Unknown	1	0.6×	0.914

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
CCNE1	Other/Unknown	no		Cyclin_C-dom, Cyclin_N, Cyclin-like_dom
ERBB2	Kinase	yes	2.7.10.1	Rcpt_L-dom, Prot_kinase_dom, Ser-Thr/Tyr_kinase_cat_dom
ATM	Kinase	yes	2.7.11.1	PI3/4_kinase_cat_dom, PIK-rel_kinase_FAT, FATC_dom

Expression context

Cohort genes with no expression data: 0.

3 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
adrenal tissue	1
oocyte	1
secondary oocyte	1
lower esophagus mucosa	1
right uterine tube	1
sural nerve	1
calcaneal tendon	1
colonic epithelium	1
corpus callosum	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
CCNE1	201	ubiquitous	marker	secondary oocyte, oocyte, adrenal tissue
ERBB2	276	ubiquitous	marker	lower esophagus mucosa, right uterine tube, sural nerve
ATM	286	ubiquitous	marker	calcaneal tendon, colonic epithelium, corpus callosum

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
ERBB2	9,659
ATM	7,383
CCNE1	3,811

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
ERBB2	P04626	63
CCNE1	P24864	22
ATM	Q13315	14

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 126. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
p53-Dependent G1 DNA Damage Response	2	475.8×	3e-04	CCNE1, ATM
p53-Dependent G1/S DNA damage checkpoint	2	475.8×	3e-04	CCNE1, ATM
G1/S DNA Damage Checkpoints	2	447.8×	3e-04	CCNE1, ATM
DNA Damage/Telomere Stress Induced Senescence	2	108.8×	0.003	CCNE1, ATM
Cellular Senescence	2	91.7×	0.004	CCNE1, ATM
PLCG1 events in ERBB2 signaling	1	951.7×	0.007	ERBB2
Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes	1	951.7×	0.007	CCNE1
Drug-mediated inhibition of ERBB2 signaling	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to trastuzumab	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to sapitinib	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to tesevatinib	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to neratinib	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to osimertinib	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to afatinib	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to AEE788	1	951.7×	0.007	ERBB2
Resistance of ERBB2 KD mutants to lapatinib	1	951.7×	0.007	ERBB2
Drug resistance in ERBB2 TMD/JMD mutants	1	951.7×	0.007	ERBB2
Cell Cycle Checkpoints	2	59.0×	0.007	CCNE1, ATM
Transcriptional Regulation by TP53	2	41.4×	0.007	CCNE1, ATM
GRB7 events in ERBB2 signaling	1	634.4×	0.009	ERBB2
Sensing of DNA Double Strand Breaks	1	634.4×	0.009	ATM
PTK6 Regulates Cell Cycle	1	634.4×	0.009	CCNE1
Cellular responses to stress	2	24.6×	0.012	CCNE1, ATM
Cell Cycle	2	24.0×	0.012	CCNE1, ATM
RHOBTB3 ATPase cycle	1	380.7×	0.013	CCNE1
TP53 Regulates Transcription of Caspase Activators and Caspases	1	317.2×	0.013	ATM
Constitutive Signaling by Overexpressed ERBB2	1	317.2×	0.013	ERBB2
Pexophagy	1	317.2×	0.013	ATM
Defective homologous recombination repair (HRR) due to PALB2 loss of function	1	317.2×	0.013	ATM
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	1	292.8×	0.013	CCNE1

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
protein phosphorylation	3	68.0×	4e-04	CCNE1, ERBB2, ATM
positive regulation of cell adhesion	2	181.2×	0.002	ERBB2, ATM
telomere maintenance	2	178.3×	0.002	CCNE1, ATM
establishment of RNA localization to telomere	1	2808.7×	0.007	ATM
establishment of protein-containing complex localization to telomere	1	2808.7×	0.007	ATM
positive regulation of telomerase catalytic core complex assembly	1	2808.7×	0.007	ATM
pre-B cell allelic exclusion	1	1872.4×	0.007	ATM
cellular response to nitrosative stress	1	1872.4×	0.007	ATM
heart development	2	52.5×	0.007	ERBB2, ATM
immature T cell proliferation in thymus	1	1123.5×	0.008	ERBB2
peptidyl-serine autophosphorylation	1	1123.5×	0.008	ATM
negative regulation of telomere capping	1	1123.5×	0.008	ATM
regulation of telomere maintenance via telomerase	1	936.2×	0.008	ATM
negative regulation of immature T cell proliferation in thymus	1	936.2×	0.008	ERBB2
ERBB2-ERBB4 signaling pathway	1	936.2×	0.008	ERBB2
positive regulation of telomere maintenance via telomere lengthening	1	936.2×	0.008	ATM
lipoprotein catabolic process	1	802.5×	0.008	ATM
V(D)J recombination	1	702.2×	0.008	ATM
positive regulation of mesenchymal stem cell proliferation	1	702.2×	0.008	CCNE1
regulation of microtubule-based process	1	624.1×	0.008	ERBB2
meiotic telomere clustering	1	624.1×	0.008	ATM
female meiotic nuclear division	1	561.7×	0.008	ATM
ERBB2-ERBB3 signaling pathway	1	561.7×	0.008	ERBB2
ERBB2-EGFR signaling pathway	1	561.7×	0.008	ERBB2
histone mRNA catabolic process	1	561.7×	0.008	ATM
cellular response to X-ray	1	561.7×	0.008	ATM
DNA double-strand break processing	1	510.7×	0.008	ATM
enzyme-linked receptor protein signaling pathway	1	432.1×	0.009	ERBB2
regulation of autophagosome assembly	1	374.5×	0.010	ATM
pexophagy	1	351.1×	0.010	ATM

Therapeutics

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 0

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
CCNE1	PALBOCICLIB
ERBB2	CLOTRIMAZOLE
ATM	AMIODARONE HYDROCHLORIDE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ERBB2	83	4
CCNE1	38	4
ATM	35	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
PALBOCICLIB	4	CCNE1
ABEMACICLIB	4	CCNE1
GILTERITINIB	4	CCNE1
TRILACICLIB	4	CCNE1
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
CABOZANTINIB	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
PACLITAXEL	4	ERBB2
LAZERTINIB	4	ERBB2

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
ERBB2	1,221	Binding:1136, Functional:79, ADMET:6
CCNE1	691	Binding:690, ADMET:1
ATM	240	Binding:233, Functional:5, ADMET:2

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ERBB2	2.7.10.1	receptor protein-tyrosine kinase
ATM	2.7.11.1	non-specific serine/threonine protein kinase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
CCNE1	691
ERBB2	1,221
ATM	240

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

28 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
PALBOCICLIB	4	CCNE1
ABEMACICLIB	4	CCNE1
GILTERITINIB	4	CCNE1
TRILACICLIB	4	CCNE1
CLOTRIMAZOLE	4	ERBB2
ERLOTINIB HYDROCHLORIDE	4	ERBB2
PONATINIB	4	ERBB2
AFATINIB	4	ERBB2
LAPATINIB DITOSYLATE	4	ERBB2
SORAFENIB	4	ERBB2
NERATINIB	4	ERBB2
IBRUTINIB	4	ERBB2
AFATINIB DIMALEATE	4	ERBB2
DACOMITINIB	4	ERBB2
DACOMITINIB ANHYDROUS	4	ERBB2
VANDETANIB	4	ERBB2
TRIBROMSALAN	4	ERBB2
BOSUTINIB	4	ERBB2
BITHIONOL	4	ERBB2
ASTEMIZOLE	4	ERBB2
EBASTINE	4	ERBB2
OSIMERTINIB	4	ERBB2
BRIGATINIB	4	ERBB2
ACALABRUTINIB	4	ERBB2
ZANUBRUTINIB	4	ERBB2
TUCATINIB	4	ERBB2
TIRABRUTINIB	4	ERBB2
LAZERTINIB	4	ERBB2

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	CCNE1, ERBB2, ATM
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 50.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	24
PHASE1	12
PHASE3	7
Not specified	4
PHASE2/PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03422198	PHASE3	RECRUITING	Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
NCT03914612	PHASE3	ACTIVE_NOT_RECRUITING	Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
NCT05256225	PHASE3	RECRUITING	Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
NCT00006011	PHASE3	COMPLETED	Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00807768	PHASE3	UNKNOWN	Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
NCT00942357	PHASE3	UNKNOWN	Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
NCT02065687	PHASE2/PHASE3	UNKNOWN	Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
NCT02501954	PHASE3	COMPLETED	Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol
NCT00977574	PHASE2	ACTIVE_NOT_RECRUITING	Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
NCT03660826	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
NCT04719273	PHASE2	ACTIVE_NOT_RECRUITING	Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
NCT05231122	PHASE2	RECRUITING	Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT05870761	PHASE2	ACTIVE_NOT_RECRUITING	Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma
NCT05902988	PHASE1/PHASE2	RECRUITING	A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT06369155	PHASE2	RECRUITING	Azenosertib in Uterine Serous Carcinoma: Biomarker Study
NCT00478426	PHASE2	COMPLETED	Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT00492778	PHASE2	UNKNOWN	Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
NCT00888173	PHASE2	COMPLETED	Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01005329	PHASE2	COMPLETED	Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
NCT01010126	PHASE2	COMPLETED	Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
NCT01132820	PHASE2	COMPLETED	Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01210222	PHASE2	COMPLETED	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT01225887	PHASE2	COMPLETED	Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01307631	PHASE2	COMPLETED	Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
NCT01642082	PHASE2	COMPLETED	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01935934	PHASE2	COMPLETED	Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT02112552	PHASE2	TERMINATED	Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
NCT02728258	PHASE2	COMPLETED	Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
NCT02874430	PHASE2	TERMINATED	Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
NCT03836157	PHASE2	WITHDRAWN	Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
NCT04080284	PHASE2	COMPLETED	Trial of Maintenance With Niraparib- Uterine Serous Carcinoma
NCT04590248	PHASE2	COMPLETED	A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
NCT04814108	PHASE2	COMPLETED	A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
NCT02142803	PHASE1	ACTIVE_NOT_RECRUITING	TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
NCT03120624	PHASE1	ACTIVE_NOT_RECRUITING	VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
NCT06476808	PHASE1	RECRUITING	A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
NCT00005830	PHASE1	COMPLETED	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00005840	PHASE1	COMPLETED	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
NCT00575952	PHASE1	COMPLETED	Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer
NCT01440998	PHASE1	COMPLETED	Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	8
CABOZANTINIB	4	3
METFORMIN	4	2
MIRVETUXIMAB SORAVTANSINE	4	2
TEMSIROLIMUS	4	2
CAPIVASERTIB	4	1
COPANLISIB	4	1
DOSTARLIMAB	4	1
FILGRASTIM	4	1
HYALURONIDASE (HUMAN RECOMBINANT)	4	1
IXABEPILONE	4	1
NINTEDANIB	4	1
NIRAPARIB	4	1
PACLITAXEL	4	1
PEGFILGRASTIM	4	1
PEMBROLIZUMAB	4	1
PERTUZUMAB	4	1
SUNITINIB MALATE	4	1
CEDIRANIB MALEATE	3	2
BRIVANIB ALANINATE	3	1
DALANTERCEPT	3	1
TREBANANIB	3	1
AZENOSERTIB	2	2
ADAVOSERTIB	2	1
ONAPRISTONE	2	1
SAPANISERTIB	2	1
UPROSERTIB	2	1
ZENIDOLOL	2	1
CHEMBL48	0	1
CHEMBL3109278	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 4 predictive associations from 4 curated evidence items; also 1 prognostic.

Molecular subtype	Therapy	Effect	Level	CIViC
ERBB2 Amplification	Trastuzumab + Carboplatin/Paclitaxel Regimen	Sensitivity/Response	CIViC B	EID11322
ERBB2 Overexpression	Carboplatin + Paclitaxel + Trastuzumab	Sensitivity/Response	CIViC B	EID7386
ERBB2 Amplification	Trastuzumab	Sensitivity/Response	CIViC C	EID1097
CCNE1 Amplification	Taselisib + Fadraciclib	Sensitivity/Response	CIViC D	EID10181